Every Major Pharma Company Wants to Treat Cancer With Radioactive Drugs. The Isotope Supply Chain Was Built for 1,500 Patients.

Sixty-three gigabecquerels. That is roughly how much actinium-225 the world produces each year from its two traditional generator sources at Oak Ridge National Laboratory in Tennessee and the Institute for Theoretical and Experimental Physics in Moscow. At a standard therapeutic dose of approximately 40 megabecquerels administered four times per patient, that annual output covers about 1,500 people. One prostate cancer diagnosis is made every 2.4 minutes in the United States alone, meaning the entire global annual supply of actinium-225 could theoretically be consumed by the patients diagnosed in a single large American hospital network over the course of one year.

This is not an abstract supply-chain problem. It already happened. In 2024, when Novartis shut down production of its radioligand therapies Pluvicto and Lutathera at facilities in New Jersey and Italy over quality concerns, patients who were mid-treatment found themselves placed on waitlists for eight months. Cancer does not wait. Those were beta-emitting therapies based on lutetium-177, the easier isotope, the one with an established supply chain, the one Novartis had already spent billions to commercialize. Alpha-emitting therapies based on actinium-225, which deliver radiation with 50 to 1,000 times the biological potency of beta particles, face constraints that make the Pluvicto shortage look like a logistics hiccup.

The Math Nobody Ran

Market projections for radiopharmaceuticals cluster around $26.5 billion by 2031, according to Insight Partners via PharmExec's 2026 Pipeline Report, up from $9.1 billion in 2023. A separate MarketsandMarkets analysis values radioligand therapies specifically at $2.36 billion in 2024, growing to $10.91 billion by 2035 at a 13.2% compound annual growth rate, and while these numbers encompass diagnostics and beta-emitters alongside alpha therapies, actinium-225 is where the clinical excitement, the investor frenzy, and the supply crisis all converge into a single chokepoint.

Here is the calculation. Pluvicto, the most commercially advanced radioligand therapy, costs approximately $42,500 per infusion for a six-dose course totaling roughly $255,000. If Ac-225-based alpha therapies reach similar pricing and the addressable market hits even 10% of the projected $26.5 billion by 2031, that implies roughly 100,000 patients per year. If treatment costs drop with scale and competition, driving volumes higher, the number could exceed 300,000. Against a current supply of 1,500 patients' worth of Ac-225, the shortfall ranges from 67x to more than 200x, and every month of delay in closing that gap represents thousands of patients who could have benefited from targeted alpha therapy but instead received conventional chemotherapy or palliative care. Staggering. Even the most conservative projection requires a 50-fold increase in production capacity within five years, built on an isotope with a 10-day half-life that cannot be stockpiled and must be produced continuously near the point of use.

Consider insulin as a counterpoint. More than 537 million people worldwide have diabetes, served by thousands of manufacturing sites operated by dozens of companies across six continents, while Ac-225 serves 1,500 patients from roughly five production sites, none of which operated at what the industry would call commercial scale until January 2026.

The Production Race

That changed when NorthStar Medical Radioisotopes announced successful routine commercial-scale production of non-carrier-added Ac-225 using electron-accelerator technology at its Beloit, Wisconsin campus. NorthStar achieved weekly production of milli-Curie levels with high radionuclidic purity sufficient for clinical-grade radiolabeling, and the FDA accepted its Drug Master File, which means any pharmaceutical company developing an Ac-225-based drug can now reference NorthStar's isotope manufacturing data in its own regulatory filings without duplicating the validation work from scratch. NorthStar's approach bypasses nuclear reactors entirely, using electron beams to irradiate radium-226 targets, which means it is faster to site, faster to permit, and carries none of the political baggage of reactor-based production in a regulatory environment where new reactor licenses routinely take a decade to secure.

Cardinal Health followed in April 2026, announcing a significant expansion at its Center for Theranostics Advancement in Indianapolis that has already quadrupled its weekly Ac-225 output since late 2024, with material now supporting more than 15 clinical trials worldwide. RayzeBio, a Bristol Myers Squibb subsidiary developing Ac-225-labeled PSMA therapies, publicly called Cardinal's expansion "essential for advancing targeted alpha therapies."

In Belgium, PanTera is building a dedicated Ac-225 production facility in Mol, backed by €134 million in total funding led by EQT Life Sciences, Belgium's largest life sciences investment to date. PanTera's stated goal is to supply enough isotope for 100,000 cancer patients per year by 2029. Construction is underway in Mol, with equipment integration planned for late 2026, while Germany's Eckert & Ziegler simultaneously scales its own Ac-225 production line using a thorium-229 generator approach that offers a different isotopic pathway with its own set of radiochemical dependencies and regulatory hurdles. TerraPower, the nuclear venture founded by Bill Gates that has already attracted controversy for its Natrium sodium-cooled reactor program in Wyoming, has explored reactor-based Ac-225 production through its isotope division, adding yet another technological approach to a supply chain that now spans three fundamentally different production methods.

Fourteen companies are now active in the Ac-225 supply chain, spanning accelerators, reactors, and generators, and none of them existed as Ac-225 producers five years ago. Not one.

Pharma Is Buying the Supply Chain, Not Just the Drugs

The most telling signal is where the money flows. According to PharmTech's 2026 analysis, 80% of radiopharma mergers and acquisitions in 2025 focused on manufacturing and isotope supply rather than intellectual property. Eli Lilly paid $1.4 billion for POINT Biopharma and committed an additional $1.1 billion to Aktis Oncology, because the company that built its empire on insulin decided the future of oncology runs through isotopes, not just molecules. AbbVie acquired AAA for $2.9 billion, AstraZeneca launched its own radiopharma division, and Bayer doubled down on its Xofigo franchise while Novartis committed $50 billion in US expansion with radioligand therapy infrastructure as a centerpiece.

Pharma companies have learned a hard lesson from the Pluvicto shortage, one that echoes the semiconductor panic of 2021: owning the drug means nothing if you cannot secure the isotope, just as designing the chip meant nothing when you could not book wafer capacity at TSMC. Vertical integration is the new playbook: pharma is shifting from licensing molecules to controlling production infrastructure, a move that mirrors what semiconductor companies did with chip fabs in the 2020s.

Limitations

This analysis carries significant blind spots. Published DOE reports and academic literature, not audited real-time production data, supply the ~63 GBq annual Ac-225 figure, so the actual current supply could be somewhat higher given recent expansions by Cardinal Health and NorthStar. Market projections bundling the $26.5 billion figure include diagnostics and beta-emitter therapies, which face less severe isotope constraints, so applying the full figure to the Ac-225 bottleneck overstates the crisis for radiopharmaceuticals as a whole. PanTera's 100,000-patient target for 2029 is a corporate projection that has not been independently validated and could slip if construction at the Mol facility encounters the kinds of delays that have historically plagued radiochemical manufacturing builds, and it is not a guaranteed outcome. Most critically, several new production methods (accelerator-based, cyclotron-based) are coming online without disclosing exact capacity commitments, making precise gap calculations inherently uncertain.

The Strongest Case Against Panic

Beta-emitters work. Lutetium-177, the isotope behind Pluvicto and Lutathera, has an established and rapidly expanding supply chain, treats thousands of patients annually, and carries two FDA approvals. The most commercially advanced radioligand therapies do not require Ac-225 at all. Alpha therapy's 50-1,000x biological potency advantage exists in preclinical and early clinical data, but no Ac-225-based therapy has yet reached Phase III trials. It is entirely possible that beta-emitters remain the workhorses of radioligand therapy for the next decade while alpha therapies stay confined to niche indications where beta particles fail, and the bottleneck may never bind if the drugs it would supply never reach the market.

The Bottom Line

Fourteen production ventures, more than $8 billion in pharma acquisitions, and a 67x minimum supply gap. Radiopharmaceuticals represent the rare case where the science is outrunning the supply chain by orders of magnitude rather than percentage points. That gap kills people.

What you can do: If you or someone you know has metastatic castration-resistant prostate cancer, ask your oncologist specifically about radioligand therapy eligibility and whether your treatment center has Pluvicto allocation. Patients at high-volume academic medical centers tend to get allocation faster than community oncology practices. If you are an investor evaluating radiopharma, focus on companies that control isotope supply infrastructure and manufacturing, not just drug candidates with promising clinical abstracts. Watch for enrollment announcements in 2027. A Phase III clinical trial for Ac-225-PSMA therapies is the single event that will determine whether the supply gap becomes a crisis or an expensive false alarm.